- Home
- TARS vs SYRE Comparison
TARS vs SYRE Comparison
Compare TARS & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | SYRE |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TARS | SYRE |
|---|---|---|
| Price | $71.64 | $33.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $76.56 | $56.50 |
| AVG Volume (30 Days) | 709.0K | ★ 795.0K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $366,100,000.00 | N/A |
| Revenue This Year | $147.34 | N/A |
| Revenue Next Year | $53.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 182.44 | N/A |
| 52 Week Low | $38.51 | $10.91 |
| 52 Week High | $85.25 | $35.31 |
Technical Indicators
Market Signals| Indicator | TARS | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 26.51 | 58.08 |
| Support Level | $76.91 | $30.00 |
| Resistance Level | $76.22 | $34.21 |
| Average True Range (ATR) | 3.15 | 1.83 |
| MACD | -1.09 | -0.02 |
| Stochastic Oscillator | 0.12 | 84.46 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.